Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $443000.0.

  • Anika Therapeutics' Change in Inventory fell 8524.81% to $443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year decrease of 12808.61%. This contributed to the annual value of $9.4 million for FY2024, which is 1730.43% down from last year.
  • As of Q3 2025, Anika Therapeutics' Change in Inventory stood at $443000.0, which was down 8524.81% from -$1.7 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Change in Inventory high stood at $4.7 million for Q2 2024, and its period low was -$2.4 million during Q4 2024.
  • Its 5-year average for Change in Inventory is $1.7 million, with a median of $2.4 million in 2022.
  • In the last 5 years, Anika Therapeutics' Change in Inventory surged by 69036.14% in 2022 and then tumbled by 17617.08% in 2024.
  • Over the past 5 years, Anika Therapeutics' Change in Inventory (Quarter) stood at -$498000.0 in 2021, then soared by 690.36% to $2.9 million in 2022, then increased by 6.77% to $3.1 million in 2023, then tumbled by 176.17% to -$2.4 million in 2024, then skyrocketed by 118.53% to $443000.0 in 2025.
  • Its Change in Inventory was $443000.0 in Q3 2025, compared to -$1.7 million in Q2 2025 and -$523000.0 in Q1 2025.